Related Experiment Video
Updated: Jan 6, 2026

Protocol for Microplastics Sampling on the Sea Surface and Sample Analysis
Published on: December 16, 2016
Microplastics and Cardiovascular Disease: Should Clinicians Be Paying Attention?
Pedro Rafael Vieira de Oliveira Salerno1, Ricardo J Estrada-Mendizabal1, Coral Lozada2
1Department of Medicine, NYC Health & Hospitals/Elmhurst, Icahn School of Medicine at Mount Sinai, New York , Queens, USA.
Purpose Of Review:
To provide clinicians with a concise introduction of microplastics potential role as a cardiovascular risk factor.
Recent Findings:
Microplastics have been identified in human cardiovascular tissues. In vitro and animal-based studies associate microplastics presence with increased oxidative stress, endothelial dysfunction, platelet aggregation disruption, and low-grade inflammation. Small human studies report associations between intraplaque or circulating microplastics and cardiovascular outcomes. However, these signals are associative, method-dependent, and vulnerable to exposure misclassification, co-pollutant confounding, contamination, and heterogeneous analytics. Microplastics are pervasive and biologically plausible as a cardiovascular risk factor, supported by growing in-vitro evidence and incipient human association studies. Cohesive population-level measures to curb MP pollution should be embedded within policies addressing broader environmental cardiovascular risk factors. For clinicians, it remains premature to recommend personal-level mitigation strategies, and MPs are best regarded as an emerging exposure within the patient's exposome that warrants awareness and further rigorous studies.
Insights
Microplastics are found in human cardiovascular tissues and may act as a risk factor. While research is ongoing, current evidence is associative, and personal mitigation is premature.
Area of Science:
- Environmental Health
- Cardiology
- Toxicology
Background:
- Microplastics (MPs) are increasingly recognized environmental contaminants.
- Their presence and biological effects are a growing concern in human health.
Purpose of the Study:
- To introduce clinicians to the potential role of microplastics as a cardiovascular risk factor.
- To summarize current evidence linking microplastics to cardiovascular health.
Main Methods:
- Review of in vitro and animal studies on microplastic effects.
- Analysis of small human studies investigating microplastics in cardiovascular tissues and outcomes.
- Assessment of evidence limitations including confounding factors and analytical challenges.
Main Results:
- Microplastics have been detected in human cardiovascular tissues.
- In vitro and animal studies link MPs to oxidative stress, endothelial dysfunction, and inflammation.
- Small human studies show associations between MPs and cardiovascular outcomes, but these are associative and method-dependent.
Conclusions:
- Microplastics are pervasive and biologically plausible cardiovascular risk factors.
- Current human data is associative, requiring further rigorous investigation.
- Population-level pollution control is recommended; personal mitigation is premature for clinicians.
More Related Videos
10:11Fundus Photography as a Convenient Tool to Study Microvascular Responses to Cardiovascular Disease Risk Factors in Epidemiological Studies
Published on: October 22, 2014
05:31Sampling, Sorting, and Characterizing Microplastics in Aquatic Environments with High Suspended Sediment Loads and Large Floating Debris
Published on: July 28, 2018
Related Concept Videos
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Coronary Artery Disease I: Introduction
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management